18 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients (MERCURIC)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2020,
Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omi ...
Voir le projet
13
Participants partenaires
TERMINÉ
Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,
Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet
44
Participants partenaires
TERMINÉ
A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer (GANNET53)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2019,
"Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations, and primary or acquired resistance to platinum-based chemotherapy profoundly contribute to the high mortality rate. With current standard therapy the median overall survi ...
Voir le projet
20
Participants partenaires
TERMINÉ
Metagenomics in Cardiometabolic Diseases (METACARDIS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,
METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ag ...
Voir le projet
18
Participants partenaires
TERMINÉ
Clinical Development of Nitisinone for Alkaptonuria (DEVELOPAKURE)
Date du début: 1 nov. 2012, Date de fin: 30 avr. 2018,
DevelopAKUre is a proposal to fund the clinical development of an orphan designated drug, nitisinone, for the treatment of a rare Mendelian disease, Alkaptonuria (AKU). AKU is a genetic deficiency of homogentisic acid dioxygenase, causing high levels of homogentisic acid (HGA). Oxidation of HGA to pigment polymer, termed ochronosis, alters connective tissues. This leads to multisystemic damage dom ...
Voir le projet
14
Participants partenaires
TERMINÉ
Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility (NanoAthero)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2018,
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented ...
Voir le projet
17
Participants partenaires
TERMINÉ
Molecular basis of the outer membrane permeability (TRANSLOCATION)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Voir le projet
28
Participants partenaires
TERMINÉ
Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased inciden ...
Voir le projet
13
Participants partenaires
TERMINÉ
European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet
29
Participants partenaires
TERMINÉ
Multivessel versus culprit lesion only percutaneous revascularization in patients with acute myocardial infarction complicated by cardiogenic shock (CULPRIT-SHOCK)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) represents a major European health care concern with mortality rates between 40-70%. Approximately 70-80% of these patients present with multivessel disease defined as coronary lesions in more than one vessel. The clinician is faced with the decision to either 1) intervene only on the culprit lesion acutely responsible for the i ...
Voir le projet
23
Participants partenaires
TERMINÉ
GAbapentin in Paediatric Pain (GAPP)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2017,
Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate medicinal products, in clinical practice paediatric patients are often under-treated causing profound impact on their QoL.To date, opioids, non-steroid anti-inflammatory drugs (NSAIDs), antidepressants and anticonvulsants are used to treat pain, but only few ...
Voir le projet
16
Participants partenaires
TERMINÉ
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified (CFMATTERS)
Date du début: 1 oct. 2013, Date de fin: 30 juin 2017,
Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caus ...
Voir le projet
15
Participants partenaires
TERMINÉ
Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD) (DSD-LIFE)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,
Disorders of sex development (DSD) are a conglomerate of rare diseases with an estimated incidence of 1: 4500. The causes of DSD are mainly disorders with gonadal dysgenesis, decreased androgen synthesis or function in XY males or disorders with elevated androgen production in XX females. Decision on sex of rearing is difficult in some cases as the prenatal androgen imbalances result in ambiguous ...
Voir le projet
17
Participants partenaires
TERMINÉ
Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet
39
Participants partenaires
TERMINÉ
Rapid Identification of Respiratory Tract Infections (RID-RTI)
Date du début: 1 juil. 2012, Date de fin: 31 déc. 2015,
Respiratory Tract Infections (RTIs) are caused by a variety of bacterial, viral, fungal and other pathogens. RTIs are major causes of morbidity and mortality in adults and children worldwide causing millions of deaths each year. RTIs affecting the lung parenchyma (pneumonia) can be classified into three main categories: Community Acquired Pneumonia (CAP); Hospital Acquired Pneumonia (HAP) which in ...
Voir le projet
6
Participants partenaires
TERMINÉ
Evolution and Transfer of Antibiotic Resistance (EVOTAR)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,
Antibiotics are essential therapeutics in the treatment of bacterial infections. However, the indiscriminate use of antibiotics has led to the emergence of antibiotic resistant bacteria that pose a major threat to human health as options for treating infections by these bacteria have become limited. The evolution, emergence and spread ofantibiotic resistance genes are still only poorly understood ...
Voir le projet
19
Participants partenaires
TERMINÉ
Patient-centric model for remote management, treatment and rehabilitation of autistic children (MICHELANGELO)
Date du début: 1 oct. 2011, Date de fin: 31 mars 2015,
Q- EEG is used in medical labs to determine the brain connectivity in autistic children but due to the artificial nature of this lab-based approach its validity under a real-life scenario is doubtful.Also therapeutic interventions are executed typically in a clinical setting and have a limited extension in time while it has been proved the beneficial effect of an intensive intervention.Moreover, a ...
Voir le projet
9
Participants partenaires
TERMINÉ
Mimimally invasive retrograde targeting of aCAR lentiviral vector to non-human primate motor neurons (RTLVNHP)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2015,
Lentiviral vectors pseudotyped with the rabies-G envelope have been used for the delivery of therapeutic transgenes via the peripheral intamuscular route, increasing lifespan and reducing neuromuscular deficits in mouse models of both amyotrophic lateral sclerosis and spinal muscular atrophy. Despite these successes clinical translation of gene therapy for ALS with these and other vectors with re ...
Voir le projet